Allianz Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.2M | Buy |
757,195
+50,531
| +7% | +$1.11M | 0.02% | 769 |
|
|
2026
Q1 | $15.7M | Buy |
706,664
+411,188
| +139% | +$9.83M | 0.02% | 697 |
|
|
2025
Q4 | $7.89M | Buy |
295,476
+263,603
| +827% | +$6.3M | 0.01% | 939 |
|
|
2025
Q3 | $680K | Buy |
31,873
+14,773
| +86% | +$349K | ﹤0.01% | 1787 |
|
|
2025
Q2 | $369K | Sell |
17,100
-16,500
| -49% | -$307K | ﹤0.01% | 1882 |
|
|
2025
Q1 | $558K | Sell |
33,600
-5,000
| -13% | -$90.8K | ﹤0.01% | 1842 |
|
|
2024
Q4 | $708K | Buy |
38,600
+10,600
| +38% | +$171K | ﹤0.01% | 1751 |
|
|
2024
Q3 | $431K | Buy |
+28,000
| New | +$467K | ﹤0.01% | 1890 |
|
|
2024
Q1 | – | Sell |
-6,400
| Closed | -$200K | – | 2058 |
|
|
2023
Q4 | $200K | Buy |
+6,400
| New | +$153K | ﹤0.01% | 2051 |
|
|
2022
Q3 | – | Sell |
-48,205
| Closed | -$679K | – | 1869 |
|
|
2022
Q2 | $679K | Buy |
48,205
+13,105
| +37% | +$245K | ﹤0.01% | 1805 |
|
|
2022
Q1 | $850K | Hold |
35,100
| – | – | ﹤0.01% | 1924 |
|
|
2021
Q4 | $820K | Buy |
+35,100
| New | +$706K | ﹤0.01% | 1986 |
|
|
2021
Q2 | – | Sell |
-107,185
| Closed | -$2.77M | – | 2374 |
|
|
2021
Q1 | $2.77M | Sell |
107,185
-138,388
| -56% | -$6.09M | ﹤0.01% | 1281 |
|
|
2020
Q4 | $13.1M | Sell |
245,573
-143,804
| -37% | -$7.14M | 0.01% | 754 |
|
|
2020
Q3 | $16.1M | Sell |
389,377
-26,245
| -6% | -$1.13M | 0.02% | 628 |
|
|
2020
Q2 | $20.1M | Buy |
415,622
+136,895
| +49% | +$6.57M | 0.02% | 615 |
|
|
2020
Q1 | $11.8M | Buy |
278,727
+58,760
| +27% | +$2.42M | 0.02% | 780 |
|
|
2019
Q4 | $9.41M | Buy |
219,967
+163,138
| +287% | +$7.1M | 0.01% | 1182 |
|
|
2019
Q3 | $2.06M | Sell |
56,829
-4
| -0% | -$121 | ﹤0.01% | 1811 |
|
|
2019
Q2 | $1.52M | Sell |
56,833
-4,361
| -7% | -$111K | ﹤0.01% | 1990 |
|
|
2019
Q1 | $1.64M | Buy |
61,194
+6,927
| +13% | +$162K | ﹤0.01% | 1909 |
|
|
2018
Q4 | $870K | Buy |
+54,267
| New | +$1.05M | ﹤0.01% | 2078 |
|
|
2018
Q2 | – | Sell |
-27,905
| Closed | -$627K | – | 2606 |
|
|
2018
Q1 | $627K | Hold |
27,905
| – | – | ﹤0.01% | 2337 |
|
|
2017
Q4 | $840K | Sell |
27,905
-1,148
| -4% | -$36.7K | ﹤0.01% | 2288 |
|
|
2017
Q3 | $1.09M | Sell |
29,053
-85
| -0.3% | -$2.77K | ﹤0.01% | 2219 |
|
|
2017
Q2 | $835K | Sell |
29,138
-36,195
| -55% | -$1.08M | ﹤0.01% | 2277 |
|
|
2017
Q1 | $2.24M | Buy |
65,333
+5,345
| +9% | +$189K | ﹤0.01% | 1951 |
|
|
2016
Q4 | $1.73M | Sell |
59,988
-6,204
| -9% | -$164K | ﹤0.01% | 2026 |
|
|
2016
Q3 | $2.16M | Sell |
66,192
-65,754
| -50% | -$2.23M | ﹤0.01% | 1957 |
|
|
2016
Q2 | $4.28M | Buy |
131,946
+51,196
| +63% | +$1.71M | ﹤0.01% | 1578 |
|
|
2016
Q1 | $2.26M | Buy |
80,750
+4,950
| +7% | +$108K | ﹤0.01% | 1752 |
|
|
2015
Q4 | $2.71M | Hold |
75,800
| – | – | ﹤0.01% | 1590 |
|
|
2015
Q3 | $2.51M | Hold |
75,800
| – | – | ﹤0.01% | 1522 |
|
|
2015
Q2 | $3.17M | Buy |
+75,800
| New | +$2.93M | ﹤0.01% | 1530 |
|
Other funds holding ACAD
BBA
RI
PAI
Allianz Asset Management's ACAD Position: Q2 2026 in Review
Allianz Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 7.2% in Q2 2026, buying an estimated $1.11M and bringing the position to 757,195 shares worth $19.2M. The position accounts for 0.02% of the portfolio, ranked #769.
Allianz Asset Management first reported a position in ACAD in Q2 2015 and has held it in 34 quarters since. The position peaked at $20.1M in Q2 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Allianz Asset Management held 757,195 shares of Acadia Pharmaceuticals worth $19.2M as of Q2 2026.
- Allianz Asset Management bought 50,531 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
- Acadia Pharmaceuticals made up 0.02% of Allianz Asset Management's portfolio in Q2 2026, its #769 holding.
- Allianz Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2015 and has held it in 34 quarters since.
- Allianz Asset Management's Acadia Pharmaceuticals position peaked at $20.1M in Q2 2020.
- 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.